Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB
The intestinal pathogen Clostridioides difficile is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis in humans. The symptoms of C. difficile-associated diseases (CDADs) are directly associated with the pathogen's toxins TcdA and TcdB, which enter host cells and inactivate Rho and/or Ras GTPases by glucosylation. Membrane cholesterol is crucial during the intoxication process of TcdA and TcdB, and likely involved during pore formation of both toxins in endosomal membranes, a key step after cellular uptake for the translocation of the glucosyltransferase domain of both toxins from endosomes into the host cell cytosol. The licensed drug amiodarone, a multichannel blocker commonly used in the treatment of cardiac dysrhythmias, is also capable of inhibiting endosomal acidification and, as shown recently, cholesterol biosynthesis. Thus, we were keen to investigate in vitro with cultured cells and human intestinal organoids, whether amiodarone preincubation protects from TcdA and/or TcdB intoxication. Amiodarone conferred protection against both toxins independently and in combination as well as against toxin variants from the clinically relevant, epidemic C. difficile strain NAP1/027. Further mechanistic studies suggested that amiodarone's mode-of-inhibition involves also interference with the translocation pore of both toxins. Our study opens the possibility of repurposing the licensed drug amiodarone as a novel pan-variant antitoxin therapeutic in the context of CDADs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Gut microbes - 15(2023), 2 vom: 26. Dez., Seite 2256695 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Schumacher, Judith [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.09.2023 Date Revised 05.10.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/19490976.2023.2256695 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362462593 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM362462593 | ||
003 | DE-627 | ||
005 | 20231226091309.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/19490976.2023.2256695 |2 doi | |
028 | 5 | 2 | |a pubmed24n1208.xml |
035 | |a (DE-627)NLM362462593 | ||
035 | |a (NLM)37749884 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Schumacher, Judith |e verfasserin |4 aut | |
245 | 1 | 0 | |a Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.09.2023 | ||
500 | |a Date Revised 05.10.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The intestinal pathogen Clostridioides difficile is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis in humans. The symptoms of C. difficile-associated diseases (CDADs) are directly associated with the pathogen's toxins TcdA and TcdB, which enter host cells and inactivate Rho and/or Ras GTPases by glucosylation. Membrane cholesterol is crucial during the intoxication process of TcdA and TcdB, and likely involved during pore formation of both toxins in endosomal membranes, a key step after cellular uptake for the translocation of the glucosyltransferase domain of both toxins from endosomes into the host cell cytosol. The licensed drug amiodarone, a multichannel blocker commonly used in the treatment of cardiac dysrhythmias, is also capable of inhibiting endosomal acidification and, as shown recently, cholesterol biosynthesis. Thus, we were keen to investigate in vitro with cultured cells and human intestinal organoids, whether amiodarone preincubation protects from TcdA and/or TcdB intoxication. Amiodarone conferred protection against both toxins independently and in combination as well as against toxin variants from the clinically relevant, epidemic C. difficile strain NAP1/027. Further mechanistic studies suggested that amiodarone's mode-of-inhibition involves also interference with the translocation pore of both toxins. Our study opens the possibility of repurposing the licensed drug amiodarone as a novel pan-variant antitoxin therapeutic in the context of CDADs | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Clostridioides difficile infection | |
650 | 4 | |a drug repositioning | |
650 | 4 | |a drug repurposing | |
650 | 4 | |a membrane cholesterol | |
650 | 4 | |a toxin inhibitor | |
650 | 7 | |a Anti-Arrhythmia Agents |2 NLM | |
650 | 7 | |a Amiodarone |2 NLM | |
650 | 7 | |a N3RQ532IUT |2 NLM | |
650 | 7 | |a Bacterial Toxins |2 NLM | |
650 | 7 | |a Antibodies, Bacterial |2 NLM | |
700 | 1 | |a Nienhaus, Astrid |e verfasserin |4 aut | |
700 | 1 | |a Heber, Sebastian |e verfasserin |4 aut | |
700 | 1 | |a Matylitsky, Jauheni |e verfasserin |4 aut | |
700 | 1 | |a Chaves-Olarte, Esteban |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez, César |e verfasserin |4 aut | |
700 | 1 | |a Barth, Holger |e verfasserin |4 aut | |
700 | 1 | |a Papatheodorou, Panagiotis |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Gut microbes |d 2010 |g 15(2023), 2 vom: 26. Dez., Seite 2256695 |w (DE-627)NLM199892369 |x 1949-0984 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:2 |g day:26 |g month:12 |g pages:2256695 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/19490976.2023.2256695 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 2 |b 26 |c 12 |h 2256695 |